POSTER SESSION V
Wednesday, March 28, 2007 — 9:30 AM - 12:00 Noon
Exhibit Hall B - 1
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
...then notice the 'Event Added' prompt in the toolbar above as feedback:
BREAST PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
1
Quantitative Image Analysis of HER2 Immunohistochemistry Provides a Reproducible, Accurate, and Cost-Effective Tool for HER2 Assessment of Breast Cancers
(148)
RL Judd - - Ameripath Florida, Orlando, FL
Measurement of Her-2/neu Membrane Receptor Immunoreactivity by Fully Automated Digital Image Analysis
(147)
RE Jimenez, AS Basu, S Mahooti, AS Gholap, SH Barsky - The Ohio State University College of Medicine, Columbus, OH; BioImagene, Inc, Cupertino, CA
Automated Accelerated Silver In-Situ Hybridization (SISH™) for Detection of HER2 Gene Amplification in Breast Carcinoma
(180)
BG Papouchado, E Downs-Kelly, L Pestic-Dragovich, S Hood, JD Pettay, J Myles, M Loftus, N Prescott, T Grogan, PC Roche, AS McElhinny, DJ Dabbs, WM Hanna, M Dietel, DG Hicks, R Alsabeh, WC Powell, RR Tubbs - Cleveland Clinic, Cleveland, OH; Tucson, AZ; Pittsburgh, PA; Toronto, CA; Charite & Universitatsmedizin, Berlin, Germany; Roswell Park Cancer Institute, Buffalo, NY; Cedars-Sinai Medical Center, Los Angeles, CA
The FISH 2002 Study: Comparison of Techniques To Assess the HER2 Status of Patients with Metastatic Breast Cancer
(184)
F Penault-Llorca, L Arnould, G MacGrogan, A Leroux, I Treilleux, M Antoine, MO Vilain, C Blanc-Fournier, F Ettore, V Fermeaux, C Charpin-Taranger, J Jacquemier, B Lannes, G Escourrou, M Lacroix-Triki, P Gosset, C Sagan, J Couturier, A Vincent-Salomon - GEFPICS, Cedex, France
Does Using a Higher Cut Off for the Percentage of Positive Cells Improve the Specificity of HER2 Immunostaining?
(134)
O Hameed, AL Adams, DC Chhieng - - University of Alabama School of Medicine, Birmingham, AL
Chromosome 17 Polysomy Is Common in Breast Cancer Metastases and Does Not Correlate with HER2/neu Amplification or HER2/neu 2+ Staining by Immunohistochemistry
(219)
L Varghese, S Vanderwerf, C Sweeney, C Blair, C Forster, E Gulbahce - U of MN, Minneapolis; U of UT, Salt Lake City
Effect Polysomy of Chromosome 17 on the Evaluation of HER-2/neu Status in Breast Cancer
(160)
K Lee, CL Hyun, JH Chung, G Choi, SY Park - Seoul National University College of Medicine, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea
Correlations of Chromosome 17 Number with Her2/neu Gene Copy Number by FISH and Protein Expression by IHC in Breast Invasive Ductal Carcinoma
(234)
S Zhang, SS Shah - SUNY-Upstate Medical University, Syracuse, NY
Correlation of HER2 Gene and Chromosome 17 Status with Pathologic Factors in Her2 2+ Invasive Breast Cancer
(162)
G MacGrogan, F Chibon, I de Mascarel, G Sierankowski, V Brouste - Institute Bergonié, Bordeaux, France
Truncated HER2 Receptor in Breast Cancer Correlates with Poor Prognosis and Trastuzumab Resistance
(200)
F Rojo, S Landolfi, J Lirola, J Jimenez, S Rodriguez, E Llonch, J Baselga, S Ramon y Cajal - Vall d’Hebron University Hospital, Barcelona, Spain
A New Rabbit Monoclonal Antibody, 4B5, for the IHC Determination of HER2 Status in Breast Cancer: Comparison with CB11 and FISH with Interlaboratory Reproducibility
(187)
WC Powell, DG Hicks, N Prescott, J Pettay, RB Nagle, DJ Dabbs, KM Scott, RW Brown, T Grogan, PC Roche, R Tubbs - - Ventana Medical Systems, Inc, Tucson, AZ; Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Foundation, Cleveland, OH; University of Arizona Health Sciences Center, Tucson, AZ; UPMC-Magee Women’s Hospital, Pittsburgh, PA; University of Texas Health Science Center Medical School, Houston, TX
Anti HER2 Rabbit Monoclonal Antibody SP3 Is a Better Predictor of HER2 Gene Status in Invasive Breast Carcinoma
(179)
E Orvieto, L Zanatta, S Rossi, A Furlanetto, F Canal, L Laurino, AP Dei Tos - General Hospital, Treviso, Italy
Comparison of a New Rabbit Monoclonal Anti-HER2/neu Antibody to a Commonly Used Rabbit Polyclonal Antibody
(216)
DA Turbin, K Jensen, S Leung, SE McKinney, DG Huntsman, CB Gilks, RB West - Vancouver Coastal Research Institute, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada; Stanford University Medical Center, Stanford, CA
Rabbit Monoclonal Antibodies Are Highly Cost Effective and a Reliable Alternative to Mouse Antibodies for Estrogen and Progesterone Receptor Evaluation of Breast Cancers by Immunohistochemistry
(197)
RM Rocha, CB Nunes, GFS Rocha, FSF Sanches, FN Oliveira, H Gobbi - Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Topoisomerase IIa in Invasive Breast Cancer of Older Women Correlates with Tumor Size and Presence of Ductal Carcinoma In Situ: A Tissue Microarray Study
(214)
PH Tan, A Somani, BCS Ho, HH Li, PCS Ang - Singapore General Hospital, Singapore, Singapore; National Cancer Centre, Singapore, Singapore
Topoisomerase II-alpha Gene Status and Pathologic Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Carcinoma
(183)
G Peiró, FI Aranda, E Adrover, FM Peiró, A Abuomar, M Niveiro, S Benlloch - Hospital General Universitari, Alacant, Spain
Topoisomerase II-Alpha and HER2 Gene Co-Amplification as a Predictor of Response to Therapy and Survival in HER2 Positive Metastatic Breast Carcinoma
(150)
A Kapoor, A Brufsky, S Chow, M Rosenzweig, U Surti, R Bhargava - Magee-Womens Hospital of UPMC, Pittsburgh, PA
Topoisomerase II-Alpha Gene Copy Number Alterations in ERBB2-Positive Primary Breast Carcinomas: A Fluorescence In Situ Hybridization Study
(105)
A Colomer, N Erill, M Górriz, M Verdú, R Roman, R Ibáñez, C Cordon-Cardo, X Puig - Grup Assistència, Barcelona, Spain; Barcelona, Spain
Prognostic Significance of EGFR and Phosphorylated EGFR Expression in Invasive Breast Cancer
(236)
C Zoubouli, C Magkou, I Giannopoulou, K Karali, S Markaki, E Mylona, L Nakopoulou - Attikon Hospital, Athens, Greece; Medical School, University of Athens, Athens, Greece
Patterns of Nipple Involvement by Breast Carcinoma in Mastectomies
(99)
EF Brachtel, JE Rusby, JS Michaelson, BL Smith, FC Koerner - Massachusetts General Hospital, Harvard Medical School, Boston, MA
The Superficial Margin in Skin-Sparing Mastectomies for Breast Carcinoma: Factors Predicting Involvement and Efficacy of Additional Margin Sampling
(101)
D Cao, TN Tsangaris, P Argani - - The Johns Hopkins Hospital, Baltimore, MD
Perpendicular Margin and Shaved Margin Evaluation by Pathologists Versus Separate Shaved Cavity Margin by a Breast Surgeon: Which Is More Accurate and Efficient?
(174)
M Murray, A Barrio, S Patil, E Brogi, T Nehhozina, A Heerdt, LK Tan - Memorial Sloan-Kettering Cancer Center, NY, NY
Histology of Breast Re-Excision Specimens Following Intraoperative Radiotherapy
(201)
ME Roth, CI Sartor, CA Livasy - University of North Carolina, Chapel Hill, NC; University of North Carolina, Chapel Hill, NC
Impact of Complete Removal of Breast Carcinoma by Aggressive Biopsy Techniques
(226)
YH Wen, DF Roses, DM Axelrod, AA Guth, RL Shapiro, J Cangiarella, N Ziguridis, F Darvishian, C Mercado, B Singh - New York University, New York, NY
Atypical Ductal Hyperplasia at Margin of Breast Biopsy — Is Re-Excision Indicated?
(170)
C Moung, S Arora, T Menes, IJ Bleiweiss, C Nagi, S Jaffer - The Mount Sinai Medical Center, New York, NY; City Hospital at Elmhurst, Elmhurst, NY
button next to any title to add to Itinerary Planner...
Add
